Safety effect of fermented oyster extract on the endocrine disruptor assay in vitro and in vivo

• Published in: Fisheries and Aquatic Sciences
• Main Authors: Hyesook Lee, Hyun Hwangbo, Seon Yeong Ji, Seyeon Oh, Kyung-A Byun, Joung-Hyun Park, Bae-Jin Lee, Gi-Young Kim, Yung Hyun Choi
• Format: Article in Journal/Newspaper
• Language: English
• Published: The Korean Society of Fisheries and Aquatic Science 2021
• Subjects: androgen; endocrine disruptor; estrogen; fermented oyster (fo); reproductive toxicity; Aquaculture. Fisheries. Angling; SH1-691; Crassostrea gigas
• Online Access: https://doi.org/10.47853/FAS.2021.e32; https://doaj.org/article/b0130fde8ce3446e8979d11007a4644a

Oyster (Crassostrea gigas) is a marine bivalve mollusk widely distributed in coastal areas, and have been long widely used in industrial resources. Several studies demonstrated that fermented oyster (FO) extract attribute to bone health, but whether administration of FO play as an endocrine disruptor has not been studied. Therefore, in the present study, we investigated the effect of FO on the endocrine system in vitro and in vivo. As the results of the competitive estrogen receptor (ER) and androgen receptor (AR) binding affinities, FO was not combined with ER-α, ER-β, and AR. However, 17β-estradiol and testosterone, used as positive control, were interacted with ER and AR, respectively. Meanwhile, oral administration of 100 mg/kg and 200 mg/kg of FO doesn’t have any harmful effect on the body weight, androgen-dependent sex accessory organs, estrogen-dependent-sex accessory organs, kidney, and liver in immature rats. In addition, FO supplementation has no effect on the serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, and 17β-estradiol. However, the relative weight of androgen- and estrogen-dependent organs were significantly increased by subcutaneously injection of 4.0 mg/kg of testosterone propionate (TP) and by orally administration of 1.0 μg of 17α-ethynyl estradiol (EE) in immature male and female rats, respectively. Furthermore, TP and EE administration markedly decreased the serum LH and FSH levels, which are similar those of mature Sprague-Dawley (SD) rat. Furthermore, the testosterone and 17β-estradiol levels were significantly enhanced in TP and EE-treated immature rats. Taken together, our findings showed that FO does not interact with ER and AR, suggesting consequentially FO does not play as a ligand for ER and AR. Furthermore, oral administration of FO did not act as an endocrine disruptor including androgenic activity, estrogenic activity, and abnormal levels of sex hormone, indicating FO may ensure the safety on endocrine system to develop dietary ...